echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > National Development and Reform Commission: canceling drug price limit, regardless of many new policies to be implemented

    National Development and Reform Commission: canceling drug price limit, regardless of many new policies to be implemented

    • Last Update: 2015-05-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: caixin.com not long before May 15, 2015, the national development and Reform Commission, together with the national health and Family Planning Commission, the Ministry of human resources and social security and other departments issued the notice on printing and distributing opinions on promoting drug price reform, which was decided to start from June 1“ In addition to narcotic drugs and the first category of psychotropic drugs, the government should cancel the pricing of drugs, improve the drug procurement mechanism, and play the role of medical insurance and fee control The actual transaction price of drugs is mainly formed by market competition " "The ex factory price has been liberalized in the past This time, the retail price has been released The bidding and payment that affect the formation of drug prices have not been released It is affecting the formation of prices," Li said He explained that according to the characteristics of drugs, market conditions and government management, the drugs priced by the original government will be subject to classified management in the future, which can be divided into two situations First, there are about 2000 kinds of drugs paid by the medical insurance fund Accordingly, the medical insurance department, together with the relevant departments, shall formulate the rules of the payment standard for medical insurance drugs, including the procedures, basis, methods, etc Second, through the development of medical insurance payment standards, to explore the establishment of a mechanism to guide the rational formation of drug prices Among them, patent drugs and exclusive drugs (200 drugs with insufficient market competition) should establish an open, transparent and multi-party negotiation mechanism to form prices, including medical institutions, medical insurance agencies, pharmaceutical enterprises, relevant associations and experts Blood products out of the medical insurance catalog, national unified procurement of anti immune drugs, national free AIDS antiviral treatment and contraceptives (60 kinds of special drugs), through bidding procurement or negotiation to form a price Narcotic drugs and class I psychotropic substances (40 controlled drugs) maintained the status quo After the price limit is cancelled, a new management order will be established in strengthening the comprehensive supervision of medical expenses Li Lei revealed that the Ministry of social security and the health and Family Planning Commission, together with the relevant departments, will jointly formulate the payment standard of medical insurance for hospitals, how the content is, and what kind of framework it is, is still unknown, but the new regulation "has a great impact on the drug price in the future" This standard will be issued by the end of September 2015 according to the plan During the transitional period, the medical insurance fund will temporarily pay according to the price limit policy Li Lei stressed the role of medical insurance in fee control He said that in formulating the payment standards of medical insurance, we should rely on the actual market transaction price, the supply capacity of medical insurance funds and the patient's bearing capacity In addition, medical institutions and retail pharmacies should be promoted to reduce the purchase price actively At the same time, we should strengthen the control of medical expenses, establish the reward and punishment system of medical institutions' diagnosis and treatment behavior, control the unreasonable use of drugs, medical devices and excessive diagnosis and treatment Li Lei pointed out that the cost indicators of medical institutions should be made public, the construction of information platform for drug supply and guarantee should be accelerated, and the price information should be made public Li Lei revealed that the national development and Reform Commission has begun to formulate a code of conduct for drug prices The framework is divided into three parts: one is to guide the producers and operators to make reasonable prices: fair, legal and honest; the other is to keep the past reasonable and legal rules, such as the drug price differential comparison rules; the third is to prohibit price monopoly and unfair price behavior Talking about how to improve the drug price supervision system, Li Lei also introduced the future measures In addition to establishing a comprehensive cross departmental information platform and mastering the real transaction price, we will also focus on the price monitoring of drugs with insufficient competition, including the ex factory (port) price and the actual purchase and sale price In addition, Li Lei also pointed out that in the future, we should study and judge the prices of two kinds of drugs in time and carry out special cost investigation when necessary The characteristics of these two kinds of drugs are as follows: the price changes frequently, and there is a big difference in price comparison with domestic and foreign prices Li Lei disclosed that in the future, the special inspection of drug prices will be carried out for half a year; the inspection objects include drug manufacturing and trading enterprises, medical institutions, disease prevention and control centers, blood stations and drug centralized purchasing platforms; the inspection focuses on the price of special drugs for insufficient drugs and special patients In terms of inspection contents, we will mainly crack down on ten kinds of illegal acts that disrupt the market price order by means of reform, including bid up prices, collude with each other to manipulate prices, raise prices first and then discount them, the hospital is uneasy about implementing the zero difference rate of drugs, breaking through the standard of daily average cost of low-cost drugs, breaking through the sales of the highest Zero selling price, and failing to clearly mark prices according to regulations In case of violation of the law, in addition to punishment, Li Lei also stressed media supervision and listed in the price integrity record, and proposed to cancel the qualification to participate in the bidding and not be shortlisted within two years.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.